Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareSource Georgia Fingolimod Prior Auth | OpenPay…
    Ask Trek AI about this page
    CurrentCareSource GeorgiaPolicy GA-MED-P-366579

    Fingolimod Pharmacy Prior Authorization

    Customize your policy alerts

    Sign up for caresourcegeorgia Policy GA-MED-P-366579 alerts

    Get alerted when Policy GA-MED-P-366579 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs CareSource Georgia Medicaid coverage and prior authorization for fingolimod products Gilenya and Tascenso ODT for relapsing forms of multiple sclerosis, subject to age, clinical, safety-monitoring, prescriber, dosing, and continuation-therapy requirements.

    Policy Summary
    PayerCareSource Georgia
    PolicyFingolimod Pharmacy Prior Authorization
    Policy CodePolicy GA-MED-P-366579
    Change TypeRevised
    Effective DateJune 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of the member’s age, neurologist prescription or consultation, relapsing multiple sclerosis diagnosis, and required baseline assessments.
    SourceLink
    POLICY UPDATE CHANGES

    A baseline skin examination was added to the initial authorization criteria.

    The requirement to discuss progressive multifocal leukoencephalopathy risk with the member before treatment was removed.

    The policy was updated to include fingolimod as the generic policy name and Tascenso ODT as a covered product under the policy.

    A 30-unit-per-30-day quantity limit and pediatric weight-based dosing were added to the policy.

    10 yearsMinimum age for initial authorization
    12 monthsInitial approval period
    12 monthsReauthorization approval period

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    30 per 30 daysQuantity limit
    0.5 mg or 0.25 mg dailyWeight-based dosing

    Coverage Criteria

    Initial Therapy

    Covered for initial authorization when ALL of the following criteria are met:

    ALL of the following

    • Member is at least 10 years of age.
    • Medication is prescribed by or in consultation with a neurologist.
    • Member has a documented diagnosis of a relapsing form of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease.
    • Baseline assessments completed or scheduled

      • Complete blood count (CBC).
      • Ophthalmic evaluation.
      • Cardiac evaluation with an ECG showing a QTc interval of less than 500 msec.
      • Liver function tests.
      • Skin examination.
    • Member has not experienced myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III/IV heart failure within the past 6 months.
    • Member does not have Mobitz Type II second-degree or third-degree atrioventricular (AV) block or sick sinus syndrome, unless the member has a functioning pacemaker.
    • Fingolimod will not be used concomitantly with any other disease-modifying drugs for MS.

    Tascenso ODT Requirement

    For requests for Tascenso ODT, ALL of the following product-specific criteria must be met:

    ONE of the following

    • Member has had a trial of and failed Gilenya.
    • Member is unable to swallow capsules.

    Reauthorization

    Covered for reauthorization when the following requirement is met:

    Chart notes show improvement or stabilization of signs and symptoms of disease, such as fewer relapses or no new or enlarging lesions on MRI.

    Coverage is excluded if the member has experienced any of the following within the past 6 months: myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III/IV heart failure.

    Coverage is excluded for members with Mobitz Type II second-degree or third-degree atrioventricular (AV) block or sick sinus syndrome unless the member has a functioning pacemaker.

    Fingolimod must not be used concomitantly with fingolimod-containing therapy and any other disease-modifying drugs for multiple sclerosis.

    CareSource considers fingolimod not medically necessary for the treatment of conditions not listed in this policy. For any other indication, refer to the Off-Label policy.

    Clinical Thresholds and Dosing

    Baseline cardiac evaluation
    Required testElectrocardiogram (ECG) as part of the baseline cardiac evaluation
    QTc thresholdQTc interval must be less than 500 msec
    Completion statusThe baseline cardiac evaluation must be completed or scheduled
    Minimum age
    Minimum ageAt least 10 years of age
    Authorization stageApplies to initial authorization
    PopulationIncludes pediatric members 10 years of age and older

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Pharmacy prior authorization is required for fingolimod, including Gilenya and Tascenso ODT. For initial authorization, document that all applicable clinical and safety requirements are met; approval is for 12 months when criteria are satisfied.

    • Quantity limit: 30 capsules/tablets per 30 days.
    • Dosing: adults and pediatric members age 10 years and older weighing more than 40 kg receive 0.5 mg once daily; those weighing 40 kg or less receive 0.25 mg once daily.
    Step Therapy

    Gilenya Required Before Tascenso ODT

    Tascenso ODT requires a documented Gilenya step before approval unless the member cannot swallow capsules. Establish either a trial and failure of Gilenya or the member's inability to swallow capsules.

    • The requirement applies specifically when the request is for Tascenso ODT.
    • Document the outcome of the Gilenya trial or the reason capsules cannot be swallowed.

    Clinical Background

    Fingolimod is an oral sphingosine-1-phosphate receptor modulator covered under this policy for relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Coverage includes members 10 years of age and older who meet the policy’s clinical, prescriber, safety-monitoring, and continuation requirements.

    Key Terms

    Fingolimod
    DrugFingolimod
    Drug classOral sphingosine-1-phosphate receptor modulator
    UseUsed for relapsing forms of multiple sclerosis
    Tascenso ODT
    ProductTascenso ODT
    Regulatory designation505(b)(2) product
    Reference productGilenya

    Initial Fingolimod Authorization

    Initial Fingolimod Authorization

    Initial authorization requires ALL applicable criteria:

    Fingolimod initial authorization

    • Eligibility and prescriber

      • Member is at least 10 years of age and the medication is prescribed by or in consultation with a neurologist.At least 10 years
    • Qualifying diagnosis

      • Member has clinically isolated syndrome.
      • Member has relapsing-remitting disease.

    Fingolimod Reauthorization

    Fingolimod Reauthorization

    For reauthorization, ALL of the following must be met:

    Continuation response

    • Chart notes show improvement or stabilized signs and symptoms of disease, such as fewer relapses or no new or enlarging lesions on MRI.

      Approval is for an additional 12 months.

    Product-Specific Step Requirement

    StepProductRequirement
    1Tascenso ODTMember must have tried and failed Gilenya or be unable to swallow capsules.

    Quantity Limit

    Fingolimod quantity limit
    Quantity limit30 capsules or tablets
    Limit periodPer 30 days
    Covered drugFingolimod
    Policy Summary
    PayerCareSource Georgia
    PolicyFingolimod Pharmacy Prior Authorization
    Policy CodePolicy GA-MED-P-366579
    Change TypeRevised
    Effective DateJune 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of the member’s age, neurologist prescription or consultation, relapsing multiple sclerosis diagnosis, and required baseline assessments.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and DosingAuthorization and Documentation RequirementsClinical BackgroundKey TermsInitial Fingolimod AuthorizationFingolimod ReauthorizationProduct-Specific Step RequirementQuantity Limit
    Pediatric weight-based dosing
    Higher-weight pediatric doseMembers weighing more than 40 kg receive 0.5 mg once daily
    Lower-weight pediatric doseMembers weighing less than or equal to 40 kg receive 0.25 mg once daily
    Age applicabilityThe weight-based dosing applies to pediatrics 10 years of age and older
    Documentation Required

    Diagnosis and Prescriber Documentation

    Submit documentation supporting the member's age, the prescriber's neurologist involvement, and the qualifying relapsing form of multiple sclerosis.

    • Member must be at least 10 years of age.
    • Medication must be prescribed by or in consultation with a neurologist.
    • Documented diagnosis must be a relapsing form of MS, including clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease.
    Documentation Required

    Baseline Safety Monitoring

    Document that required baseline assessments have been completed or are scheduled before initial authorization.

    • Complete blood count (CBC).
    • Ophthalmic evaluation.
    • Cardiac evaluation with ECG showing QTc interval less than 500 msec.
    • Liver function tests.
    • Skin examination.
    Documentation Required

    Safety and Concomitant-Therapy Review

    Review and document cardiovascular history, conduction disorders, and concomitant MS therapy before submitting the request.

    • No myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III/IV heart failure in the previous 6 months.
    • No Mobitz Type II second-degree or third-degree AV block or sick sinus syndrome unless the member has a functioning pacemaker.
    • Fingolimod must not be used concomitantly with another disease-modifying drug for MS.
    Documentation Required

    Tascenso ODT Documentation

    For Tascenso ODT, provide documentation that supports the required Gilenya step. The record must show either trial and failure of Gilenya or inability to swallow capsules.

    • Include chart notes or other clinical documentation describing the Gilenya trial and failure.
    • If the step is bypassed, document the member's inability to swallow capsules.
    Documentation Required

    Renewal Response Documentation

    For reauthorization, submit chart notes showing that the disease has improved or that signs and symptoms have stabilized. Approved reauthorizations extend coverage for an additional 12 months when the requirement is met.

    • Examples include fewer relapses or no new or enlarging lesions on MRI.
    Denial Risk

    Age, Prescriber, or Diagnosis Does Not Qualify

    The request does not meet initial authorization criteria when the member is under the required age, a neurologist does not prescribe or consult, or the diagnosis is not a documented qualifying relapsing form of MS.

    • Member must be at least 10 years of age.
    • Neurologist prescription or consultation is required.
    • Qualifying diagnoses include clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease.
    Denial Risk

    Required Baseline Assessments Missing

    Authorization may be denied when required baseline safety assessments are absent and have not been completed or scheduled.

    • CBC.
    • Ophthalmic evaluation.
    • ECG showing QTc interval less than 500 msec.
    • Liver function tests.
    • Skin examination.
    Denial Risk

    Cardiac Safety Criteria Not Met

    Authorization may be denied when the member has a disqualifying recent cardiovascular event or specified conduction disorder.

    • Within the past 6 months: myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III/IV heart failure.
    • Mobitz Type II second-degree or third-degree AV block or sick sinus syndrome without a functioning pacemaker.
    Denial Risk

    Concomitant MS Disease-Modifying Therapy

    Do not request approval for fingolimod used concomitantly with another disease-modifying drug for MS.

    • Confirm the member is not receiving another MS disease-modifying therapy at the same time.
    Denial Risk

    Tascenso ODT Step Requirement Not Met

    A Tascenso ODT request may be denied when the required Gilenya step is not established.

    • Documented trial and failure of Gilenya is required, unless the member is unable to swallow capsules.
    • Inability to swallow capsules must be documented when used as the basis for bypassing the Gilenya step.
    Denial Risk

    Insufficient Response for Renewal

    Reauthorization may be denied when submitted chart notes do not document improvement or stabilization of the member's MS signs and symptoms.

    • Supporting response may include fewer relapses or no new or enlarging lesions on MRI.
    • Reauthorization requires evidence of response or stable disease.
    Denial Risk

    Indication Outside Policy Scope

    Fingolimod is not medically necessary under this policy for conditions not listed in the document. Submit requests for other indications under the applicable Off-Label policy.

    • This policy covers relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
    • Use the alternate Off-Label policy pathway for other indications.
    Relapsing forms of multiple sclerosis
    Clinically isolated syndromeA relapsing form of multiple sclerosis identified by the policy
    Relapsing-remitting diseaseA relapsing form of multiple sclerosis identified by the policy
    Active secondary progressive diseaseA relapsing form of multiple sclerosis identified by the policy
    Member has active secondary progressive disease.
  1. Baseline assessments

    • A complete blood count (CBC), ophthalmic evaluation, cardiac evaluation with an ECG showing a QTc interval less than 500 msec, liver function tests, and skin examination have been completed or are scheduled.QTc less than 500 msec
  2. Cardiovascular safety

    • Member has not experienced myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III/IV heart failure during the past 6 months.No listed event in the past 6 months
  3. Conduction safety

    • Member does not have Mobitz Type II second-degree or third-degree atrioventricular (AV) block or sick sinus syndrome, unless the member has a functioning pacemaker.
  4. Concomitant therapy

    • Fingolimod will not be used concomitantly with any other disease-modifying drug for multiple sclerosis.